SCHEMBL4654716

SCHEMBL4654716

O=C(CS(=O)(=O)N1CCC(c2ccccc2)CC1)NO

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP3 P08254 6/20 0.85
MMP2 P08253 3/20 0.56
MMP13 P45452 1/20 0.56
KDM4E B2RXH2 1/20 0.51
ALDH1A1 P00352 1/20 0.51
HDAC6 Q9UBN7 3/20 0.50
HDAC3 O15379 2/20 0.50
HDAC4 P56524 2/20 0.50
HDAC1 Q13547 2/20 0.50
HDAC7 Q8WUI4 2/20 0.50
HDAC2 Q92769 2/20 0.50
HDAC10 Q969S8 2/20 0.50
HDAC11 Q96DB2 2/20 0.50
HDAC8 Q9BY41 2/20 0.50
HDAC9 Q9UKV0 2/20 0.50
HDAC5 Q9UQL6 2/20 0.50
USP5 P45974 8/20 0.49
ADAM10 O14672 1/20 0.46
MMP1 P03956 1/20 0.46
MMP9 P14780 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6585216 0.92 MMP3 (1.00) MMP3MMP2MMP13KDM4EALDH1A1
SCHEMBL6586217 0.89 MMP3 (1.00) MMP3MMP2MMP13ALDH1A1HDAC6
SCHEMBL6588226 0.82 MMP3 (0.60) MMP3MMP2MMP13KDM4EALDH1A1
SCHEMBL6585983 0.81 MMP3 (0.62) MMP3MMP2MMP13ALDH1A1HDAC6
SCHEMBL6584929 0.76 MMP3 (0.72) MMP3MMP2MMP13KDM4EALDH1A1
SCHEMBL1983277 0.75 HPGD (0.63) ALDH1A1
SCHEMBL4964431 0.74 MMP2 (0.54) MMP3MMP2MMP13KDM4EALDH1A1
SCHEMBL6590110 0.74 MMP3 (0.76) MMP3KDM4EALDH1A1HDAC6USP5
SCHEMBL6586571 0.72 MMP3 (0.95) MMP3MMP2KDM4EALDH1A1USP5
SCHEMBL5898933 0.72 MMP2 (1.00) MMP3MMP2MMP13HDAC6USP5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0930067-A2 MMP INHIBITORS FOR THE TREATMENT OF OCULAR ANGIOGENESIS Pfizer Products Inc. (US) 1999-07-21 EP claimed
EP-1602354-B1 Use of polyglutamic acid or its salts MEIJI SEIKA KAISHA (JP) 2008-11-05 EP disclosed
EP-1604647-B1 Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof CHISSO CORP (JP) 2008-05-07 EP disclosed
US-20060165636-A1 Hair treatment composition and hair cosmetic for damaged hair MEIJI SEIKA KAISHA, LTD. (JP) 2006-07-27 US disclosed
US-20060018867-A1 Cosmetic composition and production thereof ICHIMARU PHARCOS CO., LTD 2006-01-26 US disclosed
EP-1604647-A1 Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof Ichimaru Pharcos Co., Ltd. (JP) 2005-12-14 EP disclosed
EP-1602354-A1 HAIR TREATMENT COMPOSITION AND HAIR COSMETIC FOR DAMAGED HAIR Meiji Seika Kaisha, Ltd. (JP) 2005-12-07 EP disclosed
EP-1036062-B1 HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS PFIZER LTD (GB) 2004-01-02 EP disclosed
US-6495568-B1 TREATMENT OF TISSUE ULCERATION, WOUND REPAIR AND SKIN DISEASES WARNER-LAMBERT COMPANY 2002-12-17 US disclosed
EP-1036062-A1 HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS Pfizer Limited (GB) 2000-09-20 EP disclosed
EP-0930067-A2 MMP INHIBITORS FOR THE TREATMENT OF OCULAR ANGIOGENESIS Pfizer Products Inc. (US) 1999-07-21 EP disclosed
WO-1999029667-A1 HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS PFIZER LIMITED (GB) 1999-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060165636-A1 Hair treatment composition and hair cosmetic for damaged hair CUTA, COL14A1, PRKDC MMP3 272/4885MMP2 1163/4885MMP13 203/4885
US-20060018867-A1 Cosmetic composition and production thereof CUTA, PARG, TYR MMP3 1360/4885MMP2 746/4885MMP13 789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.